1. Home
  2. PAYP vs GKOS Comparison

PAYP vs GKOS Comparison

Compare PAYP & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PayPay Corporation American Depository Shares

PAYP

PayPay Corporation American Depository Shares

N/A

Current Price

$16.51

Market Cap

12.0B

Sector

Real Estate

ML Signal

N/A

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$154.73

Market Cap

10.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAYP
GKOS
Founded
2018
1998
Country
Japan
United States
Employees
N/A
N/A
Industry
Real Estate
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0B
10.6B
IPO Year
2025
2015

Fundamental Metrics

Financial Performance
Metric
PAYP
GKOS
Price
$16.51
$154.73
Analyst Decision
Buy
Strong Buy
Analyst Count
9
12
Target Price
$25.54
★ $126.92
AVG Volume (30 Days)
★ 710.9K
636.1K
Earning Date
08-12-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $507,442,000.00
Revenue This Year
N/A
$23.32
Revenue Next Year
$20.92
$27.43
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 32.33
52 Week Low
$12.07
$73.16
52 Week High
$24.89
$191.62

Technical Indicators

Market Signals
Indicator
PAYP
GKOS
Relative Strength Index (RSI) 47.88 33.05
Support Level $14.47 $145.78
Resistance Level $18.98 $161.53
Average True Range (ATR) 0.75 7.06
MACD -0.20 -2.33
Stochastic Oscillator 15.38 11.50

Price Performance

Historical Comparison
PAYP
GKOS

About PAYP PayPay Corporation American Depository Shares

PayPay is a financial technology company jointly owned by Softbank and LY. It was founded in 2018, following the success of Alipay and WeChat Pay in China, and was the pioneering code payment app in Japan. Over the past seven years, it has amassed more than 70 million users and is the market leader in code payments.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: